We are Relevant
We are pioneers in advancing a revolutionary platform of radiopharmaceuticals tailored to address unmet needs in cancer therapy. Leveraging natural human antibody fragments, we precisely target well-established cancer antigens, ensuring maximum efficacy through radiotheranostics. Our innovative CORDIA platform, we meticulously optimize the antibody carrier for size and valence, enhancing treatment outcomes. With a diverse portfolio boasting "franchise" potentials across multiple cancer indications, we are poised to make a significant impact in the field.
Key Team Members
Edgar Tenorio, DVM
Nonclinical
Dr. Tenorio has worked in the biotechnology/pharmaceutical sector for more than 25 years developing biologics (i.e., peptides, proteins [interfeons], and monoclonal antibodies) and small molecules in a variety of therapeutic areas (vaccines, inflammation, pain, Alzheimer’s, autoimmune diseases, diabetes and obesity, infectious diseases, and cancer).
For the last 15 years he has led nonclinical and/or CMC programs to take lead therapeutic candidates from preclinical to first in man (Phase 1), follow-up clinical trials (Phase 2 and 3) and NDAs. He has worked at or consulted for Neurex Corporation (PRIALT [ziconotide intrathecal infusion]), Elan Pharmaceuticals, Pepgen Corporation, KaloBios Pharmaceuticals, Achaogen (ZEMDRI® [plazomicin]), Heron Therapeutics (CINVANTI® [aprepitant injectable emulsion] and ZYNRELEF™ [Bupivacaine and Meloxicam extended-release solution]), Carmot Therapeutics, and Trellis Bioscience. Dr. Tenorio holds a Bachelor of Science degree in Biomedical Science from Texas A&M University, a Doctor of Veterinary Medicine degree from the National Autonomous University of Mexico (UNAM), and a Master of Preventive Veterinary Medicine (MPVM) degree from the University of California, Davis. Dr. Tenorio also completed a clinical residency in Laboratory Animal Medicine and a NIH post-doctoral fellowship in the Dept of Comparative Pathology and Immunology at the University of California, Davis.
Stephen C. Conley Jr.
Nonclinical
Mr. Conley has over 20 years of startup and early-stage company development, executive management, business development and marketing, having participated in the successful inception of numerous startups and active participation in early-stage development. For the last 8 years he has been working in the biopharmaceutical industry, with particular focus on early phase novel oncology and vaccine translational development.
Having most recently co-founded Relevant Biosciences, where he serves in a Corporate Operations and Business Development role and Minutemen Lifesciences Inc., currently serving as the Chairmen and CEO. Prior, Stephen served in a variety of Business Development Roles for Lincal Accelovance, a Global CRO. Before entering the Biopharmaceutical Industry His prior experience spans across diverse markets and industries, where he refined his skills in corporate governance, fundraising, business development, and marketing. This diverse background has fueled his commitment to leverage technology and data insights to make strategic decisions that define company success and reputation. Stephen's commitment to societal betterment is epitomized by his active participation in and tenure on several non-profit Boards. As a Founding Member and Executive Co-chair of The Enzler Society, his leadership galvanized the promotion of Catholic Charities' mission, underpinning their expansive social service endeavors throughout the D.C. area.
Board Members
Our Board of Directors is composed of respected leaders committed to steering our vision to fruition through strategic governance and oversight.
Jamie Oliver, PharmD
Chairman
Dr. Oliver boasts a 12-year tenure in academia and an impressive 30-year track record across the public and private sectors of the biotechnology/pharmaceutical industry, as well as contract research organizations. His diverse roles include serving as Chief Executive Officer at Phage Pharmaceuticals, Chief Medical Officer at Starton Therapeutics, Chief Science Officer at Accelovance and Ockham Oncology, Chief Operating Officer at Techniclone Pharmaceuticals and Maret Pharmaceuticals, and Managing Director with Trinity Drug Partners, a strategic consulting firm.
His unparalleled expertise in clinical development is evident through his authorship of over 50 Investigational New Drug (IND) applications, including two for radiopharmaceuticals. Dr. Oliver has actively contributed to the success of seven New Drug Applications (NDAs), notably one for a radiotheranostic. Beyond these accomplishments, he has played a pivotal role in offering strategic guidance to small to midsized biotech companies, aiding in the preparation of development plans encompassing small molecule therapeutics, radiotheranostics, immunotherapies, and cellular therapies.
Dr. Oliver's outstanding capabilities extend to corporate growth, global pharmaceutical development, translational medicine, financial stewardship, and regulatory affairs. His adeptness in team-building is reflected in the creation of robust development teams and the cultivation of corporate energy. Dr. Oliver holds a Bachelor of Science in Pharmacy (1978) and a Doctor of Pharmacy degree (1982) from Mercer University.
.png)
Khoso Blauch, MBA
Independent Director
Khoso Baluch has over 36 years of experience across global geographies in the biopharmaceutical industry. Since 2012, he has served as an independent director of Poxel S.A., a French publicly traded biotech company, chairs its compensation committee and as of March 2023 became Chairman of the Board.
He also currently serves as an independent director of Longeveron Pharmaceuticals, Inc (NASDAQ: LGVN), and serves as chair of the Audit committee and is a member of the compensation committee. He also serves as an independent director of Processa Pharmaceuticals, Inc (NASDAQ: PCSA), and serves on its audit and compensation committees. He served as the Chairman of the Board for Da Volterra, a French privately held company, from December 2021 until November 2022. From 2016 to 2021, Mr. Baluch served as the Chief Executive Officer and Board member of CorMedix, Inc., a publicly traded pharmaceutical company in the US. Mr. Baluch also held various senior positions at UCB, S.A. between January 2008 to April 2016, including Senior Vice President and President Europe, Middle East & Africa. Prior to joining UCB, Mr. Baluch worked for Eli Lilly and Company (NYSE: LLY) for 24 years, holding international positions spanning Europe, the Middle East and the United States in general management, business development, market access and product leadership. Mr. Baluch holds a B.S. in Aeronautical Engineering from City University London and an MBA from Cranfield School of Management.